Study finds patients lost more weight on Mounjaro than Ozempic (NYSE:LLY)

A brand new examine discovered that sufferers taking Eli Lilly’s (NYSE:LLY) Mounjaro misplaced considerably extra weight than these taking Novo Nordisk’s (NVO) Ozempic.

The examine, which analyzed the digital well being data of roughly 41,000 overweight or obese sufferers who took the medication, discovered that the imply loss in physique weight at three months of use was 5.9% for Mounjaro customers versus 3.6% for Ozempic customers.

At six months of use, the imply loss was 10.1% for Mounjaro customers in contrast with 5.8% for Ozempic customers. The imply physique weight reduction at 12 months was 15.3% for Mounjaro customers versus 8.3% for these utilizing Ozempic. The danger of gastrointestinal hostile occasions was comparable for each medication.

The examine was printed Monday on the JAMA Inside Medication web site.

Mounjaro’s lively ingredient is tirzepatide, whereas Ozempic’s is semaglutide. Lilly markets tirzepatide for diabetes as Mounjaro and for weight reduction as Zepbound.

Equally, Novo markets semaglutide for diabetes as Ozempic and for weight reduction as Wegovy.

Each tirzepatide and semaglutide belong to a category of medicine generally known as GLP-1s.